Enlaza Therapeutics Announces Strategic Collaboration With Vertex Pharmaceuticals
San Diego – September 2, 2025 – Cooley advised Enlaza Therapeutics, the first covalent biologics platform company, on its multi-target drug discovery collaboration with Vertex Pharmaceuticals, to utilize Enlaza’s proprietary War-Lock technology platform to develop small format drug conjugates and T-cell engagers for certain autoimmune diseases and improved conditioning in sickle cell disease and beta thalassemia. Under the terms of the collaboration, Enlaza will receive $45 million inclusive of…